Nasdaq

Rubicon Technologies, Inc. Class A Common Stock (RBT)

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
NBC4 Columbus

Renibus Therapeutics Presents Two Posters on RBT-1, a First-in-Class Preconditioning Agent, at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024 Meeting

- RBT-1 is actively enrolling in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery- SOUTHLAKE, Texas, Oct. 3, 2024 ...
FOX59 News

Renibus Reports Positive Final Results from Phase 2 Study of RBT-1, a First-in-Class Preconditioning Agent for Patients Undergoing Cardiothoracic Surgery, at the American ...

RBT-1 achieved the primary biomarker endpoint, as well as several key clinical outcome endpoints; positive data supports the potential for RBT-1 to improve postoperative outcomes in cardiothoracic ...
Investing

Rubicon Technologies Inc Class A (RBT)

This page features the latest Rubicon Technologies Inc Class A share stories and breaking news. Assess the latest information about the Rubicon Technologies Inc Class A stock. Our team of expert ...